Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST.

Kairemo K, Rohren EM, Anderson PM, Ravizzini G, Rao A, Macapinlac HA, Subbiah V.

ESMO Open. 2019 Feb 28;4(1):e000439. doi: 10.1136/esmoopen-2018-000439. eCollection 2019.

2.

An International Survey of PET/CT Clinical Reporting.

Zukotynski KA, Niederkohr RD, Greenspan BS, Prior JO, Schöder H, Seltzer MA, Rohren EM, Yoo DC.

J Nucl Med. 2019 Apr;60(4):478-479. doi: 10.2967/jnumed.118.223073. Epub 2019 Mar 15. No abstract available.

PMID:
30877176
3.

Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.

Kairemo K, Milton DR, Etchebehere E, Rohren EM, Macapinlac HA.

Curr Radiopharm. 2018;11(2):147-152. doi: 10.2174/1874471011666180629145030.

PMID:
29956640
4.

Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.

Jacene H, Gomella L, Yu EY, Rohren EM.

Clin Genitourin Cancer. 2018 Aug;16(4):e919-e926. doi: 10.1016/j.clgc.2018.03.007. Epub 2018 Mar 23. Review.

5.

Spectrum of Benign Bone Conditions on NaF-PET.

Rohren EM, Macapinlac HA.

Semin Nucl Med. 2017 Jul;47(4):392-396. doi: 10.1053/j.semnuclmed.2017.02.008. Epub 2017 Apr 18. Review.

PMID:
28583278
6.

ACR and SNMMI Joint Credentialing Statement for PET/MRI of the Body.

Subramaniam RM, Jadvar H, Colletti PM, Guimaraes A, Gullapali R, Iagaru AH, McConathy J, Meltzer CC, Nadel H, Noto RB, Packard AB, Rohren EM, Oates ME.

J Nucl Med. 2017 Jul;58(7):1174-1176. doi: 10.2967/jnumed.117.193524. Epub 2017 May 4. No abstract available.

7.

Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers.

Takeuchi S, Rohren EM, Abdel-Wahab R, Xiao L, Morris JS, Macapinlac HA, Hassan MM, Kaseb AO.

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):969-978. doi: 10.1007/s00259-016-3583-2. Epub 2016 Dec 12.

8.

Fat-Containing Hypermetabolic Masses on FDG PET/CT: A Spectrum of Benign and Malignant Conditions.

Rydzak C, Chauhan A, Gupta N, Chuang HH, Rohren EM, Bhosale PR.

AJR Am J Roentgenol. 2016 Nov;207(5):1095-1104. Epub 2016 Aug 4. Review.

PMID:
27490138
9.

IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.

Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA.

J Natl Cancer Inst. 2016 Aug 30;108(12). pii: djw182. doi: 10.1093/jnci/djw182. Print 2016 Dec.

10.

State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors.

Tamm EP, Bhosale P, Lee JH, Rohren EM.

Surg Oncol Clin N Am. 2016 Apr;25(2):375-400. doi: 10.1016/j.soc.2015.11.007. Review.

11.

Assessment of Sequential PET/MRI in Comparison With PET/CT of Pediatric Lymphoma: A Prospective Study.

Sher AC, Seghers V, Paldino MJ, Dodge C, Krishnamurthy R, Krishnamurthy R, Rohren EM.

AJR Am J Roentgenol. 2016 Mar;206(3):623-31. doi: 10.2214/AJR.15.15083.

PMID:
26901021
12.

Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy.

Etchebehere EC, Araujo JC, Milton DR, Erwin WD, Wendt RE 3rd, Swanston NM, Fox P, Macapinlac HA, Rohren EM.

Clin Nucl Med. 2016 Apr;41(4):268-73. doi: 10.1097/RLU.0000000000001118.

PMID:
26828141
13.

Comparison of Standardized Uptake Values in Normal Structures Between PET/CT and PET/MRI in a Tertiary Pediatric Hospital: A Prospective Study.

Lyons K, Seghers V, Sorensen JI, Zhang W, Paldino MJ, Krishnamurthy R, Rohren EM.

AJR Am J Roentgenol. 2015 Nov;205(5):1094-101. doi: 10.2214/AJR.15.14304.

PMID:
26496558
14.

Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.

Etchebehere EC, Milton DR, Araujo JC, Swanston NM, Macapinlac HA, Rohren EM.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):8-20. doi: 10.1007/s00259-015-3185-4. Epub 2015 Sep 29.

PMID:
26416392
15.

Qualitative FDG PET Image Assessment Using Automated Three-Segment MR Attenuation Correction Versus CT Attenuation Correction in a Tertiary Pediatric Hospital: A Prospective Study.

Lyons K, Seghers V, Williams JL, Sorensen JI, Paldino MJ, Krishnamurthy R, Rohren EM.

AJR Am J Roentgenol. 2015 Sep;205(3):652-8. doi: 10.2214/AJR.14.14231.

PMID:
26295654
16.

Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.

Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, Moody T, Macapinlac HA.

J Nucl Med. 2015 Oct;56(10):1507-12. doi: 10.2967/jnumed.115.156026. Epub 2015 Jul 1.

17.

Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival.

Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM.

J Nucl Med. 2015 Aug;56(8):1177-84. doi: 10.2967/jnumed.115.158626. Epub 2015 Jun 11.

18.

PET/Computed Tomography and Patient Outcomes in Melanoma.

Rohren EM.

PET Clin. 2015 Apr;10(2):243-54. doi: 10.1016/j.cpet.2014.12.006. Epub 2015 Feb 21. Review.

PMID:
25829089
19.

American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain.

Jadvar H, Subramaniam RM, Berman CG, Boada F, Colletti PM, Guimaraes AR, McConathy J, Meltzer CC, Noto RB, Packard AB, Rohren EM, Oates ME.

J Nucl Med. 2015 Apr;56(4):642-5. doi: 10.2967/jnumed.115.155218. Epub 2015 Mar 5. No abstract available.

20.

PET scanning: worth the cost in cancer? Not only worth the cost, but sometimes a cost-cutter!

Rohren EM.

Oncology (Williston Park). 2014 May;28(5):390, 392. No abstract available.

21.

Measuring the extent of total thyroidectomy for differentiated thyroid carcinoma using radioactive iodine imaging: relationship with serum thyroglobulin and clinical outcomes.

Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, Clayman GL, Rohren EM.

JAMA Otolaryngol Head Neck Surg. 2014 May;140(5):410-5. doi: 10.1001/jamaoto.2014.264.

PMID:
24700275
22.

SNMMI comment on ASCO 2013 "Choosing wisely" recommendation on use of PET/CT in recurrent cancer surveillance.

Rohren EM, Dillehay GL, Jadvar H.

J Nucl Med. 2014 May;55(5):699-700. doi: 10.2967/jnumed.114.139683. Epub 2014 Mar 24. No abstract available.

23.

Is imaging the extremities with PEM feasible? A novel application for a high-resolution positron emission scanner.

Rahim S, Mawlawi O, Taylor S, Millican R, Swanston NM, Brown JE, Rohren EM.

Clin Imaging. 2014 May-Jun;38(3):307-13. doi: 10.1016/j.clinimag.2013.11.013. Epub 2013 Nov 27.

24.

Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer.

Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett RL Jr, Macapinlac HA.

Eur J Nucl Med Mol Imaging. 2014 May;41(5):906-14. doi: 10.1007/s00259-013-2672-8. Epub 2014 Jan 18.

PMID:
24442598
25.

Correlation of PUV and SUV in the extremities while using PEM as a high-resolution positron emission scanner.

Rahim S, Mawlawi O, Fox P, Taylor S, Millican R, Swanston NM, Brown JE, Rohren EM.

Skeletal Radiol. 2014 Apr;43(4):453-8. doi: 10.1007/s00256-013-1795-0. Epub 2014 Jan 16.

26.

(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy.

Carkaci S, Sherman CT, Ozkan E, Adrada BE, Wei W, Rohren EM, Mawlawi OR, Ueno NT, Buchholz TA, Yang WT.

Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1809-16. doi: 10.1007/s00259-013-2506-8. Epub 2013 Jul 23.

PMID:
23877633
27.

Reporting guidance for oncologic 18F-FDG PET/CT imaging.

Niederkohr RD, Greenspan BS, Prior JO, Schöder H, Seltzer MA, Zukotynski KA, Rohren EM.

J Nucl Med. 2013 May;54(5):756-61. doi: 10.2967/jnumed.112.112177. Epub 2013 Apr 10.

28.

A software tool for stitching two PET/CT body segments into a single whole-body image set.

Chang T, Chang G, Clark JW Jr, Rohren EM, Mawlawi OR.

J Appl Clin Med Phys. 2012 May 10;13(3):3599. doi: 10.1120/jacmp.v13i3.3599.

29.

Fast Dixon whole-body MRI for detecting distant cancer metastasis: a preliminary clinical study.

Costelloe CM, Kundra V, Ma J, Chasen BA, Rohren EM, Bassett RL Jr, Madewell JE.

J Magn Reson Imaging. 2012 Feb;35(2):399-408. doi: 10.1002/jmri.22815. Epub 2011 Oct 11.

30.

Investigating the limit of detectability of a positron emission mammography device: a phantom study.

Shkumat NA, Springer A, Walker CM, Rohren EM, Yang WT, Adrada BE, Arribas E, Carkaci S, Chuang HH, Santiago L, Mawlawi OR.

Med Phys. 2011 Sep;38(9):5176-85. doi: 10.1118/1.3627149.

31.

Implementation of automated tube current modulation in PET/CT: prospective selection of a noise index and retrospective patient analysis to ensure image quality.

Jackson J, Pan T, Tonkopi E, Swanston N, Macapinlac HA, Rohren EM.

J Nucl Med Technol. 2011 Jun;39(2):83-90. doi: 10.2967/jnmt.110.075283. Epub 2011 May 12.

32.

PET/CT in a patient with adenoma malignum of the uterine cervix.

Sharp HJ, Pinnix CC, Jhingran A, Euscher ED, Rohren EM, Ramirez PT.

Clin Nucl Med. 2011 Jun;36(6):468-9. doi: 10.1097/RLU.0b013e31820aa346.

PMID:
21552028
33.

Positron emission tomography-computed tomography reporting in radiation therapy planning and response assessment.

Rohren EM.

Semin Ultrasound CT MR. 2010 Dec;31(6):516-29. doi: 10.1053/j.sult.2010.08.002. Review.

PMID:
21147379
34.

18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer.

De Giorgi U, Mego M, Rohren EM, Liu P, Handy BC, Reuben JM, Macapinlac HA, Hortobagyi GN, Cristofanilli M, Ueno NT.

J Nucl Med. 2010 Aug;51(8):1213-8. doi: 10.2967/jnumed.110.076455. Epub 2010 Jul 21.

35.

Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients.

Tonkopi E, Chi PC, Mawlawi O, Riegel AC, Rohren EM, Macapinlac HA, Pan T.

J Appl Clin Med Phys. 2010 Feb 4;11(1):3073.

36.

Sentinel node mapping in vulvovaginal melanoma using SPECT/CT lymphoscintigraphy.

Kobayashi K, Ramirez PT, Kim EE, Levenback CF, Rohren EM, Frumovitz M, Mar MV, Gayed IW.

Clin Nucl Med. 2009 Dec;34(12):859-61. doi: 10.1097/RLU.0b013e3181becdaf.

PMID:
20139817
37.

Hepatic radiation injury mimicking a metastasis on positron-emission tomography/computed tomography in a patient with esophageal carcinoma.

DeLappe EM, Truong MT, Bruzzi JF, Swisher SG, Rohren EM.

J Thorac Oncol. 2009 Nov;4(11):1442-4. doi: 10.1097/JTO.0b013e3181bbf208. No abstract available.

38.

Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis.

Costelloe CM, Rohren EM, Madewell JE, Hamaoka T, Theriault RL, Yu TK, Lewis VO, Ma J, Stafford RJ, Tari AM, Hortobagyi GN, Ueno NT.

Lancet Oncol. 2009 Jun;10(6):606-14. doi: 10.1016/S1470-2045(09)70088-9. Review.

PMID:
19482249
39.

PET Imaging of Prostate Cancer: Other Tracers.

Rohren EM, Macapinlac HA.

PET Clin. 2009 Apr;4(2):185-92. doi: 10.1016/j.cpet.2009.05.004.

PMID:
27157010
40.

18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma.

Costelloe CM, Macapinlac HA, Madewell JE, Fitzgerald NE, Mawlawi OR, Rohren EM, Raymond AK, Lewis VO, Anderson PM, Bassett RL Jr, Harrell RK, Marom EM.

J Nucl Med. 2009 Mar;50(3):340-7. doi: 10.2967/jnumed.108.058461.

41.

Positron emission tomography-CT imaging in guiding musculoskeletal biopsy.

O'Sullivan PJ, Rohren EM, Madewell JE.

Radiol Clin North Am. 2008 May;46(3):475-86, v. doi: 10.1016/j.rcl.2008.02.004.

PMID:
18707958
42.

PET and PET/CT in the Diagnosis and Staging of Esophageal and Gastric Cancers.

Erasmus JJ, Rohren EM, Hustinx R.

PET Clin. 2008 Apr;3(2):135-45. doi: 10.1016/j.cpet.2008.09.002. Epub 2008 Dec 6. Review.

PMID:
27156458
43.

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD.

J Clin Oncol. 2005 Jul 20;23(21):4652-61. Epub 2005 Apr 18.

PMID:
15837965
44.

Intense FDG uptake in a benign Hurthle cell adenoma.

Rohren EM.

Clin Nucl Med. 2004 Oct;29(10):664-6. No abstract available.

PMID:
15365450
45.

Clinical applications of PET in oncology.

Rohren EM, Turkington TG, Coleman RE.

Radiology. 2004 May;231(2):305-32. Epub 2004 Mar 24. Review.

PMID:
15044750
46.

Update in PET imaging of nonsmall cell lung cancer.

Rohren EM, Lowe VJ.

Semin Nucl Med. 2004 Apr;34(2):134-53. Review. No abstract available.

PMID:
15031813
47.

A spectrum of Doppler waveforms in the carotid and vertebral arteries.

Rohren EM, Kliewer MA, Carroll BA, Hertzberg BS.

AJR Am J Roentgenol. 2003 Dec;181(6):1695-704. Review. No abstract available.

PMID:
14627599
48.

Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy.

Rohren EM, Provenzale JM, Barboriak DP, Coleman RE.

Radiology. 2003 Jan;226(1):181-7.

PMID:
12511688
49.

Colonic uptake of Tc-99m MDP in pseudomembranous colitis.

Rohren EM, Borges-Neto S.

Clin Nucl Med. 2002 Nov;27(11):797-8. No abstract available.

PMID:
12394129
50.

Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms.

Kalady MF, Clary BM, Clark LA, Gottfried M, Rohren EM, Coleman RE, Pappas TN, Tyler DS.

Ann Surg Oncol. 2002 Oct;9(8):799-806.

PMID:
12374664

Supplemental Content

Loading ...
Support Center